Placebo News and Research

RSS

Discovery of compound that reduces hallmark lesions of Alzheimer's disease in mice

Researchers at UC Irvine have found that a new compound not only relieves the cognitive symptoms of Alzheimer's disease, but also reduces the two types of brain lesions that are hallmarks of this devastating disease, thereby blocking its progression.

7 Mar 2006

SSRI use associated with increased risk for heart patients

In a surprising finding, patients with coronary artery disease who take commonly used antidepressant drugs may be at significantly higher risk of death, Duke University Medical Center researchers have found.

7 Mar 2006

FDA grants priority review for Revlimid

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review designation to its Supplemental New Drug Application (sNDA) for REVLIMID (lenalidomide) for the treatment of relapsed or refractory multiple myeloma.

6 Mar 2006

Trials on MS drug Tysabri renews hope for sufferers

According to the results of two new trials the multiple sclerosis (MS) drug Tysabri significantly reduces the progression of the disease.

5 Mar 2006

Bone marrow stem cells do not improve cardiac function in heart attack patients

There has been increasing evidence that stem cells contribute to regeneration of cardiac tissue and the development of new blood vessels following a heart attack, thus opening up new prospects for stem-cell based therapies.

1 Mar 2006

Reaction to DTaP vaccine finds no help from ibuprofen, acetaminophen

A red splotch forms where most preschoolers get their fifth, and last, shot of the acellular diphtheria-tetanus-pertussis (DTaP) vaccine, and it can last a few days.

1 Mar 2006

FDA approves Rituxan (Rituximab)

Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.

1 Mar 2006

$Hormone therapy for advanced prostate cancer can lead to bone loss and fractures$

Hormone therapy for advanced prostate cancer can lead to bone loss and fractures

A common type of treatment used to protect bone density in menopausal women is also an effective therapy for advanced prostate cancer patients during the first year of hormone therapy, according to a new Oregon Health & Science University Cancer Institute study.

1 Mar 2006

Oral agent alendronate may help men with prostate cancer suffering from bone loss

Men with prostate cancer who experience bone loss from cancer treatment could benefit from a weekly oral therapy commonly given to women with osteoporosis, according to a study presented by the University of Pittsburgh Medical Center (UPMC) at the American Society of Clinical Oncology Prostate Cancer Symposium, Feb. 24 to 26 at the San Francisco Marriott.

27 Feb 2006

Combination of glucosamine and chondroitin sulfate may be effective in some patients with moderate-to-severe knee pain

Offering hope for millions of people who suffer the most from osteoarthritis, a study published in the New England Journal of Medicine (NEJM) has found that the combined use of two dietary supplements - glucosamine and chondroitin - provided significant pain relief from the most common form of arthritis.

24 Feb 2006

Link found between morphine addiction and the tendency to explore

The tendency to use drugs depends on each individual person. Not all those who have access to drugs become addicts, therefore there may be personality characteristics that influence their use.

24 Feb 2006

Trial of intermittent malaria treatment in children leads to 86% reduction in cases

A team of researchers from the London School of Hygiene & Tropical Medicine, working in partnership with colleagues from Senegal, has found that intermittent preventive malaria treatment of children under five has a dramatic impact on malaria frequency.

24 Feb 2006

Research points to a novel approach to treating serious Strep infections

Researchers at the University of California, San Diego (UCSD) School of Medicine have discovered that so-called flesh-eating "Strep" bacteria use a specific enzyme to break free of the body's immune system, a finding which could potentially lead to new treatments for serious infections in human patients.

24 Feb 2006